BRPI0811589A2 - Composição farmacêutica e método para tratar câncer - Google Patents

Composição farmacêutica e método para tratar câncer

Info

Publication number
BRPI0811589A2
BRPI0811589A2 BRPI0811589-3A2A BRPI0811589A BRPI0811589A2 BR PI0811589 A2 BRPI0811589 A2 BR PI0811589A2 BR PI0811589 A BRPI0811589 A BR PI0811589A BR PI0811589 A2 BRPI0811589 A2 BR PI0811589A2
Authority
BR
Brazil
Prior art keywords
pharmaceutical composition
treating cancer
cancer
treating
pharmaceutical
Prior art date
Application number
BRPI0811589-3A2A
Other languages
English (en)
Inventor
Michel C Vellard
Paul A Fitzpatrick
Emil D Kakkis
Daniel J Wendt
Mubarack Muthalif
Sean M Bell
Augustus O Okhamafe
Original Assignee
Biomarin Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40363135&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0811589(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Biomarin Pharm Inc filed Critical Biomarin Pharm Inc
Priority to BR122018072594A priority Critical patent/BR122018072594B8/pt
Publication of BRPI0811589A2 publication Critical patent/BRPI0811589A2/pt
Publication of BRPI0811589B1 publication Critical patent/BRPI0811589B1/pt
Publication of BRPI0811589B8 publication Critical patent/BRPI0811589B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/51—Lyases (4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
BRPI0811589A 2007-08-17 2008-08-15 composição farmacêutica, e, usos de uma composição farmacêutica BRPI0811589B8 (pt)

Priority Applications (1)

Application Number Priority Date Filing Date Title
BR122018072594A BR122018072594B8 (pt) 2007-08-17 2008-08-15 uso de uma composição farmacêutica

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US6612507P 2007-08-17 2007-08-17
US61/066,125 2007-08-17
PCT/US2008/009765 WO2009025760A2 (en) 2007-08-17 2008-08-15 Compositions of prokaryotic phenylalanine ammonia-lyase and methods of treating cancer using compositions thereof

Publications (3)

Publication Number Publication Date
BRPI0811589A2 true BRPI0811589A2 (pt) 2014-10-29
BRPI0811589B1 BRPI0811589B1 (pt) 2020-05-12
BRPI0811589B8 BRPI0811589B8 (pt) 2021-05-25

Family

ID=40363135

Family Applications (2)

Application Number Title Priority Date Filing Date
BRPI0811589A BRPI0811589B8 (pt) 2007-08-17 2008-08-15 composição farmacêutica, e, usos de uma composição farmacêutica
BR122018072594A BR122018072594B8 (pt) 2007-08-17 2008-08-15 uso de uma composição farmacêutica

Family Applications After (1)

Application Number Title Priority Date Filing Date
BR122018072594A BR122018072594B8 (pt) 2007-08-17 2008-08-15 uso de uma composição farmacêutica

Country Status (23)

Country Link
US (4) US7560263B2 (pt)
EP (1) EP2175875B1 (pt)
JP (1) JP5584120B2 (pt)
CN (1) CN101803492B (pt)
AR (2) AR067972A1 (pt)
AU (1) AU2008289549B2 (pt)
BR (2) BRPI0811589B8 (pt)
CA (1) CA2687028C (pt)
CL (1) CL2008002390A1 (pt)
CY (1) CY1118222T1 (pt)
DK (1) DK2175875T3 (pt)
ES (1) ES2602618T3 (pt)
HR (1) HRP20161474T1 (pt)
HU (1) HUE029510T4 (pt)
LT (1) LT2175875T (pt)
MX (1) MX2009012261A (pt)
PE (1) PE20090605A1 (pt)
PL (1) PL2175875T3 (pt)
PT (1) PT2175875T (pt)
RU (2) RU2553343C2 (pt)
SI (1) SI2175875T1 (pt)
TW (1) TWI418787B (pt)
WO (1) WO2009025760A2 (pt)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7534595B2 (en) * 2006-06-12 2009-05-19 Biomarin Pharmaceutical Inc. Compositions of prokaryotic phenylalanine ammonia-lyase and methods of using compositions thereof
US7560263B2 (en) 2007-08-17 2009-07-14 Biomarin Pharmaceutical Inc. Compositions of prokaryotic phenylalanine ammonia-lyase and methods of treating cancer using compositions thereof
EP2219602A1 (en) * 2007-11-15 2010-08-25 Amgen, Inc Aqueous formulation of erythropoiesis stimulating protein stablised by antioxidants for parenteral administration
WO2010014225A2 (en) * 2008-07-30 2010-02-04 Biomarin Pharmaceutical Inc. Assays for detection of phenylalanine ammonia-lyase and antibodies to phenylalanine ammonia-lyase
WO2011078667A2 (en) 2009-12-22 2011-06-30 Dsm Ip Assets B.V. Method of finding a biocatalyst having ammonia lyase activity
WO2011097335A2 (en) 2010-02-04 2011-08-11 Biomarin Pharmaceutical Inc. Compositions of prokaryotic phenylalanine ammonia-lyase variants and methods of using compositions thereof
WO2012075173A2 (en) 2010-12-01 2012-06-07 Board Of Regents The University Of Texas System Compositions and method for deimmunization of proteins
EP2877190B1 (en) * 2012-07-27 2016-11-02 University of North Texas Genetically modified probiotic for the treatment of phenylketonuria (pku) disease
LT2986722T (lt) * 2013-04-18 2019-09-10 Codexis, Inc. Rekombinantiniai fenilalanino amonio liazės polipeptidai
AU2014348683B2 (en) 2013-11-18 2020-11-05 Rubius Therapeutics, Inc. Synthetic membrane-receiver complexes
RU2736495C2 (ru) 2014-04-01 2020-11-17 Рубиус Терапьютикс, Инк. Способ и композиции для иммуномодуляции
EP3145536B1 (en) 2014-04-16 2021-10-27 Codexis, Inc. Engineered tyrosine ammonia lyase
WO2015165374A1 (en) 2014-04-29 2015-11-05 Bio-Cancer Treatment International Limited Methods and compositions for modulating the immune system with arginase i
US10752923B2 (en) 2014-07-14 2020-08-25 Cysbio Aps Processes for the production of hydroxycinnamic acids using polypeptides having tyrosine ammonia lyase activity
KR102438885B1 (ko) 2014-12-22 2022-09-01 코덱시스, 인코포레이티드 인간 알파-갈락토시다제 변이체
JP6994018B2 (ja) 2016-07-26 2022-01-14 バイオマリン ファーマシューティカル インコーポレイテッド 新規アデノ随伴ウイルスキャプシドタンパク質
IT201600086488A1 (it) * 2016-08-22 2018-02-22 St Microelectronics Srl Dispositivo a semiconduttore e corrispondente procedimento
CN110573175A (zh) * 2017-02-13 2019-12-13 科德克希思公司 工程化苯丙氨酸氨裂合酶多肽
SG11202010830WA (en) 2018-05-09 2020-11-27 Biomarin Pharm Inc Methods of treating phenylketonuria
TW202005978A (zh) 2018-05-14 2020-02-01 美商拜奧馬林製藥公司 新穎肝靶向腺相關病毒載體
WO2019241132A1 (en) 2018-06-12 2019-12-19 Codexis, Inc. Engineered tyrosine ammonia lyase
SG11202105668PA (en) 2018-12-14 2021-06-29 Codexis Inc Engineered tyrosine ammonia lyase
KR20210106537A (ko) 2018-12-20 2021-08-30 코덱시스, 인코포레이티드 인간 알파 갈락토시다제 변이체
US11970722B2 (en) 2019-12-20 2024-04-30 Codexis, Inc. Engineered acid alpha-glucosidase variants
AR122409A1 (es) 2020-04-03 2022-09-07 Biomarin Pharm Inc Tratamiento de la fenilcetonuria con aav y formulaciones terapéuticas
IL300533A (en) 2020-08-28 2023-04-01 Codexis Inc Transgenic variants of amylase
CN117098847A (zh) 2020-08-28 2023-11-21 科德克希思公司 工程化蛋白酶变体
US11918633B2 (en) 2021-05-19 2024-03-05 Biomarin Pharmaceutical Inc. Compositions of prokaryotic phenylalanine ammonia-lyase and methods of treating adolescent subjects

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4252822A (en) 1979-12-26 1981-02-24 Children's Hospital Medical Center Method for treating phenylketonuria
US4562151A (en) 1983-09-06 1985-12-31 Monsanto Company Stabilization of L-phenylalanine ammonia-lyase enzyme
US5206344A (en) 1985-06-26 1993-04-27 Cetus Oncology Corporation Interleukin-2 muteins and polymer conjugation thereof
US5166322A (en) 1989-04-21 1992-11-24 Genetics Institute Cysteine added variants of interleukin-3 and chemical modifications thereof
US5766897A (en) 1990-06-21 1998-06-16 Incyte Pharmaceuticals, Inc. Cysteine-pegylated proteins
US5212939A (en) * 1991-12-04 1993-05-25 Pratt Jr John M Marine mooring swivel fitting
ES2184756T3 (es) 1992-11-19 2003-04-16 Anticancer Inc Uso de metioninasa como agente antitumoral en quimioterapia antimetionina.
EP0692029B1 (en) 1992-12-04 2007-05-09 Me Medical Enzymes Ag Genetically engineered glutaminase and its use in therapy
DK75593D0 (pt) 1993-06-25 1993-06-25 Novo Nordisk As
GB9418092D0 (en) * 1994-09-08 1994-10-26 Red Cross Found Cent Lab Blood Organic compounds
KR0164757B1 (ko) * 1995-06-13 1999-01-15 김광호 공조장치의 살균집진장치와 그 방법
PT1568772E (pt) 1995-09-21 2010-04-14 Genentech Inc Variantes da hormona do crescimento humana
CU22585A1 (es) 1995-11-17 1999-11-03 Centro Inmunologia Molecular Anticuerpos monoclonales antiidiótipos (ab2) de tipo igg con alta conectividad idiotípica y composiciones farmacéuticas que los contienen. su uso como inmunoreguladores de la respuesta inmune.
US6548644B1 (en) 1997-03-10 2003-04-15 Immunex Corporation Site protected protein modification
US6183738B1 (en) 1997-05-12 2001-02-06 Phoenix Pharamacologics, Inc. Modified arginine deiminase
US5981239A (en) 1997-09-24 1999-11-09 Great Lakes Chemical Corp. Synthesis of optically active phenylalanine analogs using Rhodotorula graminis
US6451986B1 (en) 1998-06-22 2002-09-17 Immunex Corporation Site specific protein modification
US6461849B1 (en) 1998-10-13 2002-10-08 Novozymes, A/S Modified polypeptide
US6686164B1 (en) 1998-10-30 2004-02-03 Novozymes A/S Low allergenic protein variants
AU772153B2 (en) 1999-02-12 2004-04-08 Molecular Insight Pharmaceuticals, Inc. Matrices for drug delivery and methods for making and using the same
US6586398B1 (en) 2000-04-07 2003-07-01 Amgen, Inc. Chemically modified novel erythropoietin stimulating protein compositions and methods
CA2406390A1 (en) 2000-04-14 2001-10-25 University Of South Carolina Research Foundation Cloning, overexpression and therapeutic uses of bioactive histidine ammonia lyase
US6967097B2 (en) * 2000-07-24 2005-11-22 Pcbu Services, Inc. Phenylalainine ammonia lyase polypeptide and polynucleotide sequences and methods of obtaining and using same
US6939941B2 (en) * 2001-09-12 2005-09-06 Toray Fine Chemicals Co., Ltd. Preparation of polysulfide compositions
WO2003072743A2 (en) 2002-02-26 2003-09-04 E.I. Du Pont De Nemours And Company Method for the recombination of genetic elements
EP1576127A4 (en) 2002-11-14 2006-10-25 Scripps Research Inst CRYSTAL FORM OF FATTY ACID AMINE HYDROLASE (FAAH)
US7553653B2 (en) 2004-09-17 2009-06-30 Biomarin Pharmaceutical Inc. Variants and chemically-modified variants of phenylalanine ammonia-lyase
EP2886658A1 (en) 2005-03-10 2015-06-24 BASF Enzymes LLC Lyase enzymes, nucleic acids encoding them and methods for making and using them
US7531341B1 (en) 2006-06-12 2009-05-12 Biomarin Pharmaceutical Inc. Compositions of prokaryotic phenylalanine ammonia-lyase and methods of using compositions thereof
US7534595B2 (en) * 2006-06-12 2009-05-19 Biomarin Pharmaceutical Inc. Compositions of prokaryotic phenylalanine ammonia-lyase and methods of using compositions thereof
DE102006032167B4 (de) 2006-07-12 2014-11-27 Evonik Degussa Gmbh Verfahren zur Herstellung von Triallylisocyanurat (TAIC)
US20090011400A1 (en) 2006-12-01 2009-01-08 The Salk Institute for Biological Studies and The Regents of the University of California Substrate switched ammonia lyases and mutases
US7560263B2 (en) 2007-08-17 2009-07-14 Biomarin Pharmaceutical Inc. Compositions of prokaryotic phenylalanine ammonia-lyase and methods of treating cancer using compositions thereof
WO2010014225A2 (en) 2008-07-30 2010-02-04 Biomarin Pharmaceutical Inc. Assays for detection of phenylalanine ammonia-lyase and antibodies to phenylalanine ammonia-lyase

Also Published As

Publication number Publication date
LT2175875T (lt) 2016-12-12
AR117389A2 (es) 2021-08-04
RU2553343C2 (ru) 2015-06-10
RU2009141987A (ru) 2011-05-20
SI2175875T1 (sl) 2017-01-31
AU2008289549A1 (en) 2009-02-26
MX2009012261A (es) 2010-03-15
BRPI0811589B8 (pt) 2021-05-25
DK2175875T3 (en) 2016-11-21
US7537923B2 (en) 2009-05-26
CA2687028A1 (en) 2009-02-26
HUE029510T4 (en) 2017-05-29
EP2175875B1 (en) 2016-10-05
US20090263369A1 (en) 2009-10-22
CL2008002390A1 (es) 2009-05-29
HUE029510T2 (hu) 2017-02-28
JP2010536759A (ja) 2010-12-02
BR122018072594B1 (pt) 2020-10-27
AU2008289549B2 (en) 2014-02-06
PL2175875T3 (pl) 2017-04-28
HRP20161474T1 (hr) 2016-12-30
PT2175875T (pt) 2016-11-21
WO2009025760A3 (en) 2009-06-25
ES2602618T3 (es) 2017-02-21
CN101803492B (zh) 2014-05-07
PE20090605A1 (es) 2009-05-16
TW200911283A (en) 2009-03-16
JP5584120B2 (ja) 2014-09-03
RU2012134838A (ru) 2014-03-20
US7790433B2 (en) 2010-09-07
TWI418787B (zh) 2013-12-11
US20090047265A1 (en) 2009-02-19
AR067972A1 (es) 2009-10-28
CY1118222T1 (el) 2017-06-28
WO2009025760A2 (en) 2009-02-26
CN101803492A (zh) 2010-08-11
BR122018072594B8 (pt) 2021-07-27
CA2687028C (en) 2016-02-16
EP2175875A2 (en) 2010-04-21
BRPI0811589B1 (pt) 2020-05-12
US20090047268A1 (en) 2009-02-19
US7560263B2 (en) 2009-07-14
US20100278802A1 (en) 2010-11-04

Similar Documents

Publication Publication Date Title
BRPI0811589A2 (pt) Composição farmacêutica e método para tratar câncer
BRPI0919238A2 (pt) métodos e composições para o tratamento de câncer
BRPI0909164A2 (pt) método e composições para o tratamento de câncer
BR112012018951A2 (pt) composição farmacêutica, combinação farmacêutica e método para o tratamento e\ou prevenção de um câncer e anticorpo
BRPI0813725A2 (pt) Métodos e composições para tratamento de doenças
BRPI0818426A2 (pt) produto de combinação, uso de um produto de combinação, e, método para tratar câncer
BRPI0908854A2 (pt) composições e métodos para o tratamento de tumor de origem hematopoética
BRPI0921321A2 (pt) métodos para o tratamento de indwcções e tumores
BR112012018947A8 (pt) composição farmacêutica para o tratamento e/ou prevenção de um câncer, anticorpo, combinação farmacêutica e método para o tratamento e/ou prevenção de um câncer
BRPI0815387A2 (pt) composição farmacêutica, método para fazer uma composição farmacêutica e método de tratar uma condição
BRPI0911757A2 (pt) composiÇÕes e mÉtodos para tratar distérbios digestivos.
BRPI0922475A2 (pt) composto, composição farmacêutica , método para tratar câncer, e, uso de um composto.
BRPI0808115A2 (pt) Método e aparelho para coexistência
BRPI0819218A2 (pt) Métodos, estojos e composições para administração de compostos farmacêuticos
BRPI1007972A2 (pt) composições de combinação e métodos para o tratamento de câncer
BRPI0822349A2 (pt) composições e métodos para tratar doenças lisossômicas
BRPI0811059A2 (pt) combinação, composição farmacêutica, método para tratar câncer em um animal de sangue quente, e, uso de uma combinação
BRPI1008566A2 (pt) métodos e composições para o diagnóstico e tratamento de câncer
BRPI0908635A2 (pt) composto, composição farmacêutica e método de tratamento de câncer
BRPI1011325A2 (pt) composições e métodos para o tratamento de inflamação
BRPI1008564A2 (pt) métodos e composições para o dignóstico e tratamento de câncer
BRPI0815330A2 (pt) métodos e composições para tratar cânceres
BRPI0818323A2 (pt) composição farmacêutica, uso de uma composição farmacêutica, e, método para tratar câncer.
BRPI0909016A2 (pt) anticorpos úteis para o tratamento do câncer
HUP0700369D0 (en) Pharmaceutical compositions and method for treating schizofrenia

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06T Formal requirements before examination [chapter 6.20 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 12/05/2020, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 15/08/2008 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF